Skip to content
⌘KStart free
AI InfrastructureDefenseQuantumAll studies →

iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases

← catalyst calendar

NCT03549754 · readout in 1,595 d

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase
—
Status
Recruiting
Study type
Observational
Enrollment
35,000estimated
Sites
76
Countries
Brazil, Chile, Costa Rica +17

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2018-02-17actualWhen the study began enrolling
Primary completion2030-12-31estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2030-12-31estimatedThe whole study's end, after follow-up
First posted2018-06-08actualWhen this record first appeared on the registry
Results posted—When the sponsor posted results to the registry
Record updated2026-07-22actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Type 2 Diabetes
  • Hypertension
  • Chronic Kidney Disease
  • Heart Failure

Primary outcomes

what the primary-completion date above is the date OF
1. Age of particpants
measured At Baseline
2. Percentage of Participants by Sex
measured At baseline
3. Percentage of Participants by Ethnicity
measured At Baseline
4. Percentage of Participants by Education Level
measured At Baseline
5. Percentage of Participants by Marital Status
measured At Baseline
6. Percentage of Participants with Family History of Cardiovascular and Renal-Metabolic Disease
measured At Baseline
7.Percentage of Participants by Physical Activity Level
measured At Baseline
8. Percentage of Participants by Smoking Status
measured At Baseline
9. Percentage of Participants by Alcohol Consumption
measured At Baseline
10. Body Weight of Participants
measured At Baseline
11. Height of Participants
measured At Baseline
12. Body Mass Index (BMI) of Participants
measured At Baseline
13. Waist Circumference of Participants
measured At Baseline
14. Waist-to-Hip Ratio of Participants
measured At Baseline
15. Waist-to-Height Ratio of Participants
measured At Baseline
16. Percentage of Participants by Cardiac and Renal Functional Measurements Category
measured At Baseline
17. Primary Disease Duration
measured At Baseline
18. Percentage of Participants by Number and Types of Comorbidities
measured At Baseline
19. Percentage of Participants by NYHA Functional Class
measured At Baseline
20. Percentage of Participants by Heart Failure Phenotype
measured At Baseline
21. Percentage of Participants by Heart Failure Etiology
measured At Baseline
22. Percentage of Participants by CKD Etiology
measured At Baseline
23. Percentage of Participants by Hypertension Stage
measured At Baseline
24. Percentage of Participants by Secondary Hypertension Etiology
measured At Baseline
25. Office Systolic and Diastolic Blood Pressure
measured At Baseline
26. Home Blood Pressure Monitoring (HBPM) Systolic and Diastolic Values
measured At Baseline
27. Ambulatory Blood Pressure Monitoring (ABPM) Systolic and Diastolic Values
measured At Baseline
28. Blood HbA1c
measured Average of 3 years
29. Fasting Glucose
measured Average of 3 years
30. Lipid Profile Testing
measured Average of 3 years
31. Serum Creatinine
measured Average of 3 years
32. Estimated Glomerular Filtration Rate (eGFR)
measured Average of 3 years
33. Urine Albumin-to-Creatinine Ratio (UACR)
measured Average of 3 years
34. Serum Electrolyte Values
measured Avergae of 3 years
35. Frequency of HbA1c Testing
measured Average of 3 years
36. Frequency of Fasting Glucose Testing
measured Average of 3 years
37. Frequency of Lipid Profile Testing
measured Average of 3 years
38. Frequency of Serum Creatinine Testing
measured Average of 3 years
39. Frequency of eGFR Assessment
measured Average of 3 years
40. Frequency of Urine Albumin-to-Creatinine Ratio Testing
measured Average of 3 years
41. Echocardiography
measured Average of 3 years
42. Electrocardiogram (ECG)
measured Average of 3 years
43. Participants Receiving Dietary Modification Counseling
measured Average of 3 years
44. Participants Enrolled in Exercise Programs
measured Average of 3 years
45. Participants Receiving Weight Management Interventions
measured Average of 3 years
46. Participants Receiving Smoking Cessation Counseling
measured Average of 3 years
47. Participants Receiving Alcohol Reduction Counseling
measured Average of 3 years
48. Percentage of Participants by Line of Treatment
measured Average of 3 years
49. Percentage of Participants by Drug Class
measured Average of 3 years
50. Percentage of Participants Undergoing Cardiac Surgeries (CABG or PCI)
measured Average of 3 years
51. Percentage of Participants Receiving Dialysis
measured Average of 3 years
52. Percentage of Participants with Cardiac Device Implantation
measured Average of 3 years
53. Mean Duration of Pharmacological Treatments
measured Average of 3 years
54. Drug Dose of Pharmacological Treatments
measured Average of 3 years
55. Number of Primary Care Visits per Participant
measured Average of 3 years
56. Number of Tertiary Care Hospital Visits per Participant
measured Average of 3 years
57. Number of Specialist Care Visits per Participant
measured Average of 3 years
58.Number of Emergency Department Visits per Participant
measured Average of 3 years
59. All-Cause Hospitalizations
measured Average of 3 years
60. Disease-Specific Hospitalizations
measured Average of 3 years
61. All-Cause Emergency Department Visits
measured Average of 3 years
62. Disease-Specific Emergency Department Visits
measured Average of 3 years
63. Length of Hospital Stay
measured Average of 3 years

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed

Related →Calendar (CAL)Screener (SCR)Watchlist (WL)